ClinicalTrials.gg
RecruitingNCT07851636SUPERNOVA-RBTUpdated Oct 13, 2026

Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

An interventional study of Personalized Treatment Recommendation in Rare CNS Tumor, FOXR2-activated and BCOR ITD Sarcoma, sponsored by Adriana Fonseca. Recruiting at 1 site in United States. Open to participants aged Up to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Adriana Fonseca · Not applicable, Interventional, and Other

How we know

Updated Oct 13, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
Up to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.

Planned enrollment
744th of 1,192
20 · median 30
Started
2026
with 55 others
No phase
226 of 1,447
64 open now
Primary completion
2032-01
later than 340 of 353 live
Registered
1,437th of 1,447
by date

Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 744th largest by planned enrollment of the 1,192 interventional ones that give a count, is one of 56 that started in 2026, is one of 226 with no phase, reaches primary completion later than 340 of the 353 other live ones, and was the 1,437th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

227 more — sign in →

All 233 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: Up to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,447 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.

Read the detailed description

Following clinically indicated biopsy or resection, fresh tissue will be submitted for real-time high-throughput drug screening and tumor/paired-normal molecular profiling will be initiated. A specialized tumor board will issue a documented management recommendation within 28 days . Recommendations will integrate successful drug screening, all molecular/pathology data available at the time of review, prior therapy, and clinical context. Later molecular results may prompt an addendum. The treating physician retains responsibility for final treatment decisions.

03

Conditions studied

  • Rare CNS Tumor
  • FOXR2-activated
  • BCOR ITD Sarcoma
  • CNS Sarcoma
  • PLAG-altered Tumors
  • Mesenchymal Tumor

Keywords

  • Brain Tumor
  • CNS Sarcoma
  • BCOR altered tumor
  • Mesenchymal tumor
  • MN1 fused tumor
  • PATZ1 fused tumor
  • MN1 altered tumor
  • Astroblastoma
  • Drug Screening
  • Personalized Treatment
04

Who can participate

Ages eligible
Up to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have a relapse or recurrence of one of the following rare brain tumors:

    • CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
    • BCOR altered tumors (e.g. BCOR ITD; BCOR, BCORL1, EP300, fused)
    • Mesenchymal tumors (e.g. FET::CREB altered tumors)
    • MN1::PATZ1 fused tumors
    • PLAG- altered tumors
    • Astroblastomas/MN-1 altered (e.g. EWSR2BEND2 altered)
    • Unclassifiable tumors
    • Other rare brain tumors: (e.g. recently described, poorly characterized, and/or ambiguous entities)
  2. Participant must be a candidate for surgical resection or .

    • Participants must have surgically accessible disease.
  3. Prior therapy

    • The participant must have a or recurrent rare brain tumor following at least one prior therapy for initial diagnosis or previous recurrence prior to study registration:
    • Surgery followed by observation.
    • Multi-modality therapy: surgery, radiation, and/or chemotherapy
  4. Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

    • Biologic agent: Participant must have recovered from any toxicity potentially related to the agent.
    • Last radiation at least 7 days prior to therapy start
  5. 50 for participants > 16 years of age and Lansky 50 for participants \<16 years of age
  6. : Subjects who are receiving dexamethasone or equivalent must be on a stable or decreasing dose for at least 1 week prior to therapy start.
  7. The effects of the agents used in this study on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of therapy administration.
  8. Adequate neurologic function defined as:

    • Participants with seizure disorders may be enrolled if seizures are well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.
  9. A legal parent or guardian must be able to understand and agree to sign a written and assent document, as appropriate.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
  2. Women of must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required prior to start of therapy.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Personalized Treatment Recommendation

    Participants will be provided a treatment recommendation by the tumor board within 28 days from tissue acquisition. Based on the results of the real-time, High-throuput drug screeningRNA sequencing (RNAseq), whole genome sequencing (WGS), and clinical details of each subject's tumor.

    Other: Personalized Treatment Recommendation

Interventions

  • OtherPersonalized Treatment Recommendation

    Specialized Treatment Plan of up to four FDA approved drugs based on participant's screening results will be assigned by Rare Brain Tumor specialized tumor board. Recommendations will be provided and to primary physician.

    Also known as: Individualized treatment plan, Specialized treatment plan

06

What researchers measure

Primary outcomes

  1. Number of participants for whom a treatment recommendations are completed within 28 calendar days from tissue collection.

    Time from tissue collection to generation of tumor board recommendations will be used to determine the feasibility of using the results of real-time high-throughput screening, WGS and RNAseq of participant-derived specimens to guide treatment recommendations by a specialized tumor board, in a clinically-actionable timeframe, for children and young adults with recurrent ultra-rare brain tumors. Participants are expected to receive treatment plan within 28 calendar days.

    Time frame: Up to 28 calendar days

Secondary outcomes

  1. Proportion of participants with Adverse events

    Proportion of participants with grade 3 or higher toxicities as per the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Serious adverse events (SAEs), unexpected adverse reactions, and adverse events of special interest. Adverse events will be summarized by maximum grade and relationship to the drugs recommended by the tumor board.

    Time frame: Up to 1 year

  2. The preliminary clinical activity of tumor board-recommended treatment

    Best overall radiographic response (CR , PR, SD, PD) as per RAPNO criteria in patients receiving tumor board-recommended treatment.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jan 2032, 63 months later.

Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 63 months is close to that.

Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Oct 1, 2026
StartEst.
Oct 2026
Primary completionEst.
Jan 2032
CompletionEst.
Oct 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
Children's National Hospital is now Recruiting
Oct 13, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    Children's National Hospital is now Recruiting
    + 1 other change: verification date
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851636
Lead sponsor
Adriana Fonseca
Responsible party
Adriana Fonseca (Director of the Rare Brain Tumor Program; Attending Neuro-Oncologist, Children's National Research Institute) — Sponsor-investigator
First posted
Oct 1, 2026
Start date
Oct 2026 (estimated)
Primary completion
Jan 2032 (estimated)
Completion
Oct 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Rachel Reed, MS, CCRP
Contact
rreed@childrensnational.org
202-476-5111
Hope Lovell
Contact
hlovell@childrensnational.org
202-476-3898
Adriana Fonseca, MD
principal investigator · Children's National Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion